Skip to the answer

Adagrasib

Adagrasib is a targeted cancer medicine used to treat certain adults with KRAS G12C-mutated non-small cell lung cancer or colorectal cancer that has spread or cannot be removed by surgery.

Brand name Krazati
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 7, 2026
Adagrasib at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Adagrasib (Krazati) is a targeted cancer medicine, on the U.S. market since about 2022, for adults with advanced non-small cell lung cancer or colorectal cancer (alongside cetuximab) whose tumor carries the KRAS G12C mutation and who have been treated before; it works by permanently shutting down that mutated growth-driving protein. Nausea, vomiting and diarrhea are very common, can turn severe, and usually need medicines to keep them in check. Heart rhythm is the thing to watch, since it can lengthen the QT interval (the heart's electrical reset), so expect ECGs (heart tracings) plus electrolyte and liver checks. It interacts with many drugs, so every prescriber should know you take it.

Clinical pearls

  • Report any new cough, breathlessness or fever right away, since lung inflammation (pneumonitis) is a rare but serious risk.
  • Swallow tablets whole, with or without food; if you vomit after a dose, skip the repeat and wait for the next.
  • Itraconazole, rifampin, warfarin, digoxin and midazolam all clash with adagrasib, so have your pharmacy screen every new prescription.
  • Use effective contraception during treatment, and avoid breastfeeding until one week after the last dose.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet
Earliest FDA record2022
Companies listing it with the FDA1
FDA label last updatedMar 25, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Adagrasib, written from its FDA label.

What Adagrasib is used for

▾

Adagrasib is a prescription cancer medicine approved for use in adults whose tumors have a specific genetic mutation called KRAS G12C, confirmed by an FDA-approved test.

  • Krazati (adagrasib) — as a single agent — treats adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have already received at least one prior systemic (whole-body) therapy
  • Krazati (adagrasib) — in combination with cetuximab — treats adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
  • Both uses were approved under the FDA's accelerated approval program based on tumor response rate and duration of response; continued approval may depend on results from confirmatory trials

How Adagrasib works

▾

Adagrasib targets a mutated protein called KRAS G12C, which acts like a stuck accelerator in cancer cells — constantly telling them to grow and divide. Adagrasib binds permanently (irreversibly) to the mutant form of this protein at a specific spot (a mutant cysteine), locking it in an inactive state so it can no longer send those growth signals. Crucially, it only affects the mutant version; the normal KRAS protein is left alone.

When adagrasib is combined with cetuximab for colorectal cancer, the two drugs together have shown greater anti-tumor activity in certain KRAS G12C-mutant colorectal cancer models than either drug used alone — likely because they block different parts of the same cancer-driving pathway.

Adagrasib dosage

▾

Krazati tablets are taken by mouth twice daily at the same time each day. They can be taken with or without food — even a high-fat meal does not meaningfully affect how the drug is absorbed. Tablets must be swallowed whole; do not chew, crush, or split them.

  • If you vomit after a dose, do not take an additional dose — continue with your next scheduled dose
  • If you miss a dose and more than 4 hours have passed since it was due, skip it and resume your normal schedule
  • Your doctor may lower the dose or pause treatment if side effects become difficult to manage — follow their guidance carefully

Dosing details from the FDA-approved label

From the Adagrasib prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Locally advanced or metastatic NSCLC with KRAS G12C mutation (single agent)
    • 600 mg orally twice daily until disease progression or unacceptable toxicity
    • Swallow tablets whole, do not chew, crush or split
    • Take at the same time every day with or without food; if vomiting occurs after a dose, do not take an additional dose; skip a missed dose if greater than 4 hours have elapsed from the expected dosing time
  • Locally advanced or metastatic CRC with KRAS G12C mutation (in combination with cetuximab)
    • 600 mg orally twice daily until disease progression or unacceptable toxicity
    • Refer to the cetuximab prescribing information for cetuximab dosage
    • Take at the same time every day with or without food; withhold or permanently discontinue cetuximab when KRAZATI is withheld or permanently discontinued
  • Dose reductions for adverse reactions (single agent or with cetuximab)
    • First dose reduction: 400 mg twice daily
    • Second dose reduction: 600 mg once daily
    • Maximum: A maximum of two dose reductions are permitted
    • Permanently discontinue in patients unable to tolerate 600 mg once daily
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION • Recommended dosage as a single agent for NSCLC and in combination with cetuximab for CRC: 600 mg orally twice daily. ( 2.2 ) • Swallow tablets whole with or without food. ( 2.2 ) 2.1 Patient Selection Non-Small Cell Lung Cancer Select patients for treatment of locally advanced or metastatic NSCLC with KRAZATI based on the presence of KRAS G12C mutation in plasma or tumor specimens [see Clinical Studies (14.1) ] . If no mutation is detected in a plasma specimen, test tumor tissue. Colorectal Cancer Select patients for treatment of locally advanced or metastatic CRC with KRAZATI based on the presence of KRAS G12C mutation in tumor specimens [see Clinical Studies (14.2) ] . Information on FDA-approved tests for the detection of a KRAS G12C mutation is available at: https://www.fda.gov/CompanionDiagnostics 2.2 Recommended Dosage The recommended dosage of KRAZATI as a single agent or in combination with cetuximab is 600 mg orally twice daily until disease progression or unacceptable toxicity. Refer to the cetuximab prescribing information for cetuximab dosage information [see Clinical Studies (14.2) ] . Take KRAZATI at the same time every day with or without food [see Clinical Pharmacology (12.3) ]. Swallow tablets whole. Do not chew, crush or split tablets. If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time. If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time. 2.3 Dosage Modifications for Adverse Reactions Recommended dose reductions for adverse reactions for use of KRAZATI as a single agent or in combination with cetuximab are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily. Table 1: Recommended KRAZATI Dosage Reductions for Adverse Reactions Dose Reduction Dosage First dose reduction 400 mg twice daily Second dose reduction 600 mg once daily Refer to the cetuximab prescribing information for dose modifications for adverse reactions associated with cetuximab. When KRAZATI is administered in combination with cetuximab, withhold or permanently discontinue cetuximab when KRAZATI is withheld or permanently discontinued.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Adagrasib side effects

▾

Most people taking adagrasib experience some side effects, especially affecting the digestive system. The most common ones include:

Common side effects

  • Nausea, vomiting, and diarrhea
  • Fatigue
  • Musculoskeletal pain (muscle and joint pain)
  • Decreased appetite
  • Swelling (edema)
  • Shortness of breath
  • Dizziness
  • Abnormal liver blood tests
  • Elevated liver enzymes on blood tests
  • When used with cetuximab for colorectal cancer: skin rash and dry skin are also very common

When to get medical help

  • Call your doctor right away if you have severe or persistent nausea, vomiting, or diarrhea that isn't controlled with supportive care
  • Seek immediate help for an irregular or fast heartbeat, dizziness, fainting, or palpitations — these may signal a dangerous heart rhythm problem
  • Tell your doctor if you notice yellowing of the skin or eyes, dark urine, or severe abdominal pain — these can be signs of liver injury
  • Get medical attention for new or worsening cough, shortness of breath, or fever — these may indicate lung inflammation (interstitial lung disease or pneumonitis)
  • Report any signs of gastrointestinal bleeding such as blood in stool or vomit

Adagrasib warnings and precautions

▾
  • Gastrointestinal reactions: Nausea, diarrhea, and vomiting are extremely common and can be severe. Serious complications like GI bleeding or bowel obstruction have also occurred. Supportive care medicines are usually given alongside adagrasib, and the dose may need adjustment.
  • QTc prolongation (heart rhythm changes): Adagrasib lengthens the QT interval — a measurement of the heart's electrical cycle — in a dose-dependent way. This can increase the risk of dangerous arrhythmias, including a potentially life-threatening rhythm called torsades de pointes. Avoid other QT-prolonging drugs. ECG and electrolyte monitoring are required, especially in at-risk patients.
  • Liver toxicity (hepatotoxicity): Elevated liver enzymes and, in rare cases, drug-induced liver injury have been reported. Liver function tests are checked before starting and regularly during treatment. Dose reductions or discontinuation may be needed.
  • Interstitial lung disease (ILD) / pneumonitis: Serious, sometimes fatal lung inflammation has occurred. Report any new or worsening cough, shortness of breath, or fever immediately. Adagrasib will be paused or permanently stopped if ILD/pneumonitis is suspected or confirmed.

Adagrasib interactions

▾

Adagrasib has several important drug interactions because it is processed by — and also affects — key liver enzymes and drug transporters.

  • Strong CYP3A4 inducers (e.g., rifampin): Dramatically reduce adagrasib blood levels, making it much less effective — avoid combining
  • Strong CYP3A4 inhibitors (e.g., itraconazole): Can increase adagrasib levels before it reaches steady state (about 8 days in) — avoid combining during this early period
  • Sensitive CYP3A4 substrates (e.g., midazolam): Adagrasib significantly raises their levels, increasing toxicity risk — avoid combining
  • Sensitive CYP2C9 substrates (e.g., warfarin): Adagrasib increases their levels — avoid when small concentration changes could be dangerous
  • Sensitive CYP2D6 substrates: Adagrasib raises their levels — avoid when small changes matter clinically
  • P-glycoprotein (P-gp) substrates (e.g., digoxin): Adagrasib can increase their levels — use caution or avoid when safety margin is narrow
  • Other QT-prolonging drugs: Combining with adagrasib amplifies the risk of dangerous heart arrhythmias — avoid whenever possible

Interactions listed in the FDA-approved label

From the Adagrasib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inducers: Adagrasib is a CYP3A4 substrate; concomitant use reduces adagrasib exposure, which may reduce the effectiveness of KRAZATI. Avoid concomitant use.
  • Strong CYP3A4 inhibitors: If adagrasib concentrations have not reached steady state, concomitant use will increase adagrasib concentrations, which may increase the risk of KRAZATI adverse reactions. Avoid concomitant use until adagrasib concentrations have reached steady state (after approximately 8 days).
  • Sensitive CYP3A substrates: Adagrasib is a CYP3A inhibitor; concomitant use increases exposure of CYP3A substrates, which may increase the risk of adverse reactions related to these substrates. Avoid concomitant use unless otherwise recommended in the Prescribing Information for these substrates.
  • Sensitive CYP2C9 substrates: Adagrasib is a CYP2C9 inhibitor; concomitant use increases exposure of CYP2C9 substrates, which may increase the risk of adverse reactions related to these substrates. Avoid concomitant use where minimal concentration changes may lead to serious adverse reactions, unless otherwise recommended in the Prescribing Information for these substrates.
  • Sensitive CYP2D6 substrates: Adagrasib is a CYP2D6 inhibitor; concomitant use increases exposure of CYP2D6 substrates, which may increase the risk of adverse reactions related to these substrates. Avoid concomitant use where minimal concentration changes may lead to serious adverse reactions, unless otherwise recommended in the Prescribing Information for these substrates.
  • P-gp substrates: Adagrasib is a P-gp inhibitor; concomitant use increases exposure of P-gp substrates, which may increase the risk of adverse reactions related to these substrates. Avoid concomitant use where minimal concentration changes may lead to serious adverse reactions, unless otherwise recommended in the Prescribing Information for these substrates.
  • Drugs that prolong the QTc interval: Concomitant use may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de pointes, other serious arrythmias, and sudden death. Avoid concomitant use. If it cannot be avoided, monitor electrocardiogram and electrolytes prior to starting KRAZATI, during concomitant use, and as clinically indicated. Withhold KRAZATI if the QTc interval is > 500 ms or the change from baseline is > 60 ms.
Read the label’s full interactions text

7 DRUG INTERACTIONS See full prescribing information for clinically significant drug interactions with KRAZATI. ( 7 ) • Strong CYP3A4 Inducers : Avoid concomitant use. ( 7.1 ) • Strong CYP3A4 Inhibitors : Avoid concomitant use until adagrasib concentrations have reached steady state. ( 7.1 ) • Sensitive CYP3A4 Substrates : Avoid concomitant use with sensitive CYP3A4 substrates. ( 7.2 ) • Sensitive CYP2C9 or CYP2D6 Substrates or P-gp Substrates : Avoid concomitant use with sensitive CYP2C9 or CYP2D6 substrates or P-gp substrates where minimal concentration changes may lead to serious adverse reactions. ( 7.2 ) • Drugs That Prolong QT Interval : Avoid concomitant use with KRAZATI. ( 7.3 ) 7.1 Effects of Other Drugs on KRAZATI Strong CYP3A4 Inducers Avoid concomitant use of KRAZATI with strong CYP3A inducers. Adagrasib is a CYP3A4 substrate. Concomitant use of KRAZATI with a strong CYP3A inducer reduces adagrasib exposure [see Clinical Pharmacology (12.3) ] , which may reduce the effectiveness of KRAZATI. Strong CYP3A4 Inhibitors Avoid concomitant use of KRAZATI with strong CYP3A inhibitors until adagrasib concentrations have reached steady state (after approximately 8 days). Adagrasib is a CYP3A4 substrate. If adagrasib concentrations have not reached steady state, concomitant use of a strong CYP3A inhibitor will increase adagrasib concentrations, [see Clinical Pharmacology (12.3) ], which may increase the risk of KRAZATI adverse reactions. 7.2 Effects of KRAZATI on Other Drugs Sensitive CYP3A Substrates Avoid concomitant use of KRAZATI with sensitive CYP3A substrates unless otherwise recommended in the Prescribing Information for these substrates. Adagrasib is a CYP3A inhibitor. Concomitant use with KRAZATI increases exposure of CYP3A substrates [see Clinical Pharmacology (12.3) ] , which may increase the risk of adverse reactions related to these substrates.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿178 supplements and herbs with documented Adagrasib interactions, ranked by severity Check Adagrasib against a supplement or herb →

Before taking Adagrasib

▾
  • A confirmed KRAS G12C mutation on an FDA-approved test is required before starting adagrasib — it will not work without this mutation
  • Patients with congenital long QT syndrome or an already-prolonged QT interval should avoid adagrasib
  • Patients with congestive heart failure, slow heart rate, or electrolyte imbalances need careful monitoring of heart rhythm and blood chemistry
  • Pregnancy: There are no human data, but animal studies showed harm at certain exposures. Use effective contraception during treatment; discuss with your doctor
  • Breastfeeding: Do not breastfeed during treatment with Krazati or for 1 week after the last dose due to potential harm to the infant
  • Fertility: Adagrasib may impair fertility in both women and men based on animal data — discuss family planning with your doctor before starting
  • Children: Safety and effectiveness have not been established in pediatric patients
  • Older adults (65+): No meaningful differences in safety or effectiveness compared to younger patients, but standard monitoring still applies
  • Kidney or liver impairment: No clinically significant changes in drug levels are expected in patients with mild to severe kidney or liver impairment, but your doctor should still be aware of your full health history

What Adagrasib does in the body

▾

Adagrasib lengthens the QTc interval — a measure of the heart's electrical recovery time — in a concentration-dependent way. At typical therapeutic blood levels, the average increase in the QTcF interval (a corrected measure) is approximately 18 milliseconds. This effect is the reason heart monitoring (ECGs) and electrolyte checks are built into the treatment plan. The full relationship between drug exposure and its anti-tumor effects has not been fully characterized.

How your body processes Adagrasib

▾

After an oral dose, adagrasib reaches peak blood levels in about 6 hours, and it can be taken with or without food without meaningfully affecting absorption. The drug has a half-life of about 23 hours, meaning it takes roughly a day for blood levels to fall by half, and it takes about 8 days of twice-daily dosing to reach steady-state (stable) levels in the body. Adagrasib is metabolized primarily by liver enzymes (especially CYP3A4) and is about 98% bound to proteins in the blood. It is eliminated mainly through the feces (about 75% of a dose), with a small amount cleared through urine. Age, sex, race, body weight, and mild-to-severe kidney or liver impairment do not significantly alter how the body processes adagrasib.

How to store Adagrasib

▾

Store tablets at room temperature, 20°C to 25°C (68°F to 77°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

178

Supplements & herbs that interact with Adagrasib

178 supplements and herbal products have documented interactions with Adagrasib in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 11
  • Moderate · 132
  • Minor · 35
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major ARSENIC Major BEER Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIBERIAN COCKLEBUR Major +170 more
Every supplement checked against Adagrasib — ranked by severity The full interaction hub: 11 major · 132 moderate · 35 minor · every one linked to its full report. Check Adagrasib against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Adagrasib: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Adagrasib — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Krazati (adagrasib) and why was it prescribed to me?

▾
Krazati is a targeted therapy — meaning it goes after a specific abnormality in your cancer cells rather than attacking all rapidly dividing cells the way traditional chemotherapy does. It's prescribed when your tumor has been found to carry a specific mutation called KRAS G12C. If you have non-small cell lung cancer with this mutation and have already had at least one prior treatment, Krazati can be used on its own. If you have colorectal cancer with this mutation and have had certain prior chemotherapy, Krazati is used together with another medicine called cetuximab. Your doctor will only prescribe it if your tumor tested positive for the KRAS G12C mutation on an approved test.

What side effects should I expect, and which ones mean I should call someone right away?

▾
The most common side effects are nausea, diarrhea, and vomiting — these happen in the vast majority of people taking Krazati. Fatigue, muscle and joint pain, decreased appetite, and swelling are also common. Your team will likely give you medicines to help manage the nausea and diarrhea, so don't try to just push through without telling them. What you do need to act on right away: chest pounding, an irregular heartbeat, or fainting (possible heart rhythm issues); yellowing of your skin or eyes, or dark urine (possible liver problem); or new coughing, shortness of breath, or fever that seems to come on suddenly (possible lung inflammation). These need to be reported the same day — call your oncology team or go to urgent care.

Do I need to take Krazati with food, and are there any foods or drinks I need to avoid?

▾
The good news is that food doesn't significantly affect how Krazati is absorbed, so you can take it with or without a meal — whichever works better for your stomach. That said, if you're struggling with nausea, some people find it easier to take with a light snack. There are no specific foods listed as interactions, but it's always worth letting your pharmacist know about any herbal supplements or vitamins you're taking, since some can affect how Krazati works in your body.

I take several other medications. Is that a concern with Krazati?

▾
Yes, drug interactions are genuinely important with Krazati. It affects several liver enzymes that process other drugs, which means it can raise or lower the levels of many common medicines in your blood. Certain antibiotics (like rifampin), antifungals (like itraconazole), blood thinners (like warfarin), heart rhythm medicines, and sedatives can all interact with it. You should also avoid other medications that affect the heart's QT interval — the electrical rhythm — because Krazati already has that effect on its own, and combining them raises the risk of a serious arrhythmia. Bring a complete list of everything you take — prescription, over-the-counter, and supplements — to your oncologist and pharmacist before you start.

Can I get pregnant or breastfeed while on Krazati?

▾
Pregnancy and breastfeeding are not safe during treatment with Krazati. Animal studies suggest it could harm a developing baby, and there are no human safety data yet. If you could become pregnant, you'll need to use effective birth control during treatment. Because it's unknown whether adagrasib passes into breast milk, you should not breastfeed while taking Krazati and for at least one week after your last dose. It's also worth knowing that Krazati may affect fertility in both women and men based on animal studies, so if having children in the future is important to you, have that conversation with your doctor before you begin.

What happens if I miss a dose or accidentally throw up right after taking it?

▾
If you vomit after taking your dose, don't take another one — just wait until your next scheduled dose and carry on normally. If you miss a dose and it's been more than 4 hours since you were supposed to take it, skip that dose entirely and resume your regular twice-daily schedule. Never double up to make up for a missed dose. Krazati works best when taken consistently at the same times each day, so setting a daily alarm can really help.

Is Adagrasib available over the counter?

▾
No. Adagrasib is a prescription medicine: every Adagrasib product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Adagrasib first available?

▾
The earliest FDA record we hold for Adagrasib is from 2022: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Adagrasib was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Adagrasib on HelloPharmacist

📊Adagrasib supplement interactions178 checked — ranked by severity 🌿Drug & Supplement CheckerAdagrasib vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Adagrasib NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Adagrasib Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Adagrasib forms and strengths (how it comes)

Adagrasib is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Adagrasib inactive ingredients by manufacturer.

Tablet

By mouth
Brands Krazati
How this form is used
What it may be used for
  • Krazati is used as a single agent to treat adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have had at least one prior treatment
  • Krazati is used in combination with cetuximab to treat adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer who have had prior chemotherapy with specific regimens
Important instructions
  • Krazati tablets are taken by mouth twice daily, with or without food
  • Swallow Krazati tablets whole — do not chew, crush, or split them
  • If you vomit after taking Krazati, do not take an extra dose; take the next dose at the regular scheduled time
  • If you miss a Krazati dose and more than 4 hours have passed since it was due, skip that dose and resume your normal schedule
Available strengths 1 strength
200 mg
4 FDA-listed product records ⓘ

Adagrasib on the U.S. market: products, makers and brands

How Adagrasib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Adagrasib product record with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2022. Brand names on the directory include Krazati; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
1
FDA-listed product records ⓘ
2022
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

How widely Adagrasib is used (Medicaid data)

A general measure of how commonly Adagrasib is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Adagrasib is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

278
Medicaid prescriptions filled (Q1–Q4 2025)
$4.9M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Adagrasib prescribed? Of the 1,601 medications we measure, Adagrasib ranks #1,429 by Medicaid prescriptions — more than 11% of them.

Where Adagrasib ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,429 of 1,601
#1,424 Tesamorelin Injection 287 Rx #1,425 Lopinavir and Ritonavi... 282 Rx #1,426 Methyldopa 282 Rx #1,427 Methyl Salicylate 282 Rx #1,428 Methamphetamine 281 Rx #1,429 Adagrasib 278 Rx #1,430 Eravacycline Injection 277 Rx #1,431 Brodalumab Injection 273 Rx #1,432 Elotuzumab Injection 269 Rx #1,433 Bexarotene 266 Rx #1,434 Dexrazoxane Injection 265 Rx

Utilization by Adagrasib product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

adagrasib 200 MG Oral Tablet

278 Medicaid prescriptions (Q1–Q4 2025) 100% of Adagrasib prescriptions shown $4.9M gross reimbursement (before rebates) ≈ $17,702 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2625917

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Adagrasib, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 4 listed Adagrasib NDCs with Medicaid activity.

Compare Adagrasib products

A representative set of FDA-listed product records for Adagrasib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
200 mg Oral Mirati Therapeutics, Inc NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Adagrasib NDCs →

Adagrasib recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Adagrasib recalls since July 2021.

✅No Adagrasib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Adagrasib RxCUI 2625882 1 dose form · 1 strength
  1. Dose form (SCDF) Oral Tablet RxCUI 2625916 In current FDA listings
    Clinical drug / strength (SCD) 200 MG RxCUI 2625917

Look up RxCUI 2625882 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Adagrasib brand names

Adagrasib is sold under one brand name in the FDA directory — Krazati. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Krazati

Who makes Adagrasib: manufacturers and labelers

One company lists Adagrasib products with the FDA. By number of product records, the largest are Mirati Therapeutics, Inc. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Mirati Therapeutics, Inc 1

Adagrasib drug class (RxNorm)

Adagrasib belongs to the Other antineoplastic agents class.

Drug family (ATC) Other antineoplastic agents

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Adagrasib page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Mar 25, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Adagrasib.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Adagrasib after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Mirati Therapeutics, Inc
Linked label effective
Mar 25, 2026
Composite sections available
21
Linked SPL Set ID
0b8bf078-34c2-4f45-9012-38a8ac082b01
Linked SPL Document ID
65724d4c-78ab-4d85-83b5-73b9da5c2cc3
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Mirati Therapeutics, Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →